MAPK

MEK-IN-8 is a potent MEK inhibitor with an IC50 of less than 5 nM for phosphorylated MEK in A549 cells. This compound is valuable for investigating the MEK/ERK signaling pathway and its role in tumorigenesis. MEK-IN-8 is a useful tool for preclinical studies aimed at understanding cancer biology and potential therapeutic interventions.

MS910 is a potent and selective PROTAC degrader targeting MEK1 and MEK2 kinases. It demonstrates effective degradation of MEK1 and MEK2 in various cancer cell lines, with reported DC50 values of 118 nM for MEK1 and 55 nM for MEK2 in HT-29 cells, and 94 nM for MEK1 and 38 nM for MEK2 in SK-MEL-28 cells. MS910 is primarily utilized in cancer research to explore the therapeutic potential of targeted protein degradation.

MEK4 inhibitor-2 is a selective inhibitor targeting the MEK4 pathway, exhibiting an IC50 of 83 nM. It demonstrates significant biological activity against pancreatic adenocarcinoma, making it a valuable reagent for cancer research. This compound can be utilized in studies exploring the role of MEK4 in tumor progression and therapeutic responses.

Pimasertib hydrochloride is a selective allosteric inhibitor of MEK1/2, functioning through non-competitive inhibition of ATP-binding. This compound is notable for its ability to effectively block the MAPK signaling pathway, which is crucial in various cancers. Pimasertib is utilized in research focused on cancer therapeutics and cell signaling mechanisms, making it a valuable tool for studying tumor progression and drug resistance.

BAY-866 is an allosteric inhibitor of MEK1, exhibiting an IC50 of 14 nM. This compound effectively inhibits cell proliferation in A375 (BRAF) and HCT116 (K-Ras) cell lines, with respective IC50 values of 13 nM and 277 nM. Additionally, BAY-866 demonstrates anti-tumor activity in K-Ras-mutated A549 xenograft models, making it a valuable tool for research in cancer biology and targeted therapies.

(R)-PD 0325901CL is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), a key regulator in the MAPK signaling pathway. This compound demonstrates significant antitumor activity, effectively inhibiting the proliferation of cancer cells both in vitro and in vivo. Its utility in cancer research makes it a valuable reagent for studies focused on targeted therapies and the elucidation of MEK-related mechanisms in oncogenesis.

MEK-IN-4 is a potent MEK inhibitor that specifically targets the MEK signaling pathway. It demonstrates significant biological activity in modulating cellular responses associated with inflammatory disorders and various types of cancer. This compound is an invaluable tool for research applications focused on understanding MEK-related signaling mechanisms in disease processes and therapeutic interventions.

Polfurmetinib hydrate is a potent MEK inhibitor, exhibiting an IC50 of 2 nM against A375 melanoma cells. This compound effectively hinders the MEK signaling pathway, making it a valuable tool for studies of cancer biology and therapeutic development. Its selective inhibition of MEK allows for insights into cellular signaling mechanisms and contributes to research on targeted cancer therapies.

MEK-IN-1 is a selective inhibitor of MEK (Mitogen-Activated Protein Kinase Kinase), targeting the MAPK signaling pathway. It demonstrates significant anti-proliferative effects on various cancer cell lines by blocking MEK-mediated phosphorylation of downstream ERK proteins. This compound is valuable for research applications focused on cancer biology, specifically in understanding MEK/ERK signaling and exploring therapeutic strategies for MEK-related malignancies.

UC-773587 is a selective inhibitor of SOS1 catalytic activity. By specifically binding to the catalytic site of SOS1, it inhibits nucleotide exchange with an IC50 of 4.5 μM, while demonstrating minimal interaction with HRas and ITSN. This compound is valuable for research into signaling pathways and has potential applications in the study of prostate cancer.

PROTAC SOS1 ligand 1 is a high-affinity ligand for the SOS1 protein, facilitating targeted protein degradation through PROTAC technology. This compound is instrumental in the development of therapeutic strategies by enabling the selective modulation of SOS1, which plays a pivotal role in various oncogenic signaling pathways. Researchers can utilize this reagent in studies focused on cancer biology and drug discovery, particularly in exploring novel approaches to target and degrade specific proteins associated with tumor progression.

SOS1-IN-21 is a potent inhibitor of son of Sevenless 1 (SOS1) with an IC50 of 15 nM. As a guanine nucleotide exchange factor (GEF), SOS1 plays a critical role in the activation of KRAS by promoting GDP-GTP exchange. SOS1-IN-21 demonstrates significant antiproliferative effects, exhibiting IC50 values of 16 nM in NCI-H358 and 17 nM in Mia Paca-2 cell lines. Additionally, it shows substantial antitumor activity in the Mia Paca-2 xenograft model, making it a valuable tool for research on KRAS mutant tumors, including pancreatic cancer.

SOS1 Ligand Intermediate-7 is a critical chemical intermediate utilized in the synthesis of the SOS1 ligand, an important modulator of cellular signaling pathways. This compound plays a significant role in the production of PROTAC SOS1 degrader-1, facilitating targeted protein degradation research. Its applications extend to studies involving SOS1 activation and its implications in various biological processes.

SOS1 Ligand Intermediate-6 is a key precursor in the synthesis of SOS1 ligands, facilitating the development of targeted protein degradation technologies, such as PROTACs. This chemical reagent offers researchers a valuable tool for probing the SOS1 signaling pathway and potential therapeutic interventions. Its application in PROTAC synthesis broadens the scope for studying protein interactions and modulation in various biological systems.

SOS1 Ligand intermediate-5 is a selective ligand for the son of sevenless 1 (SOS1) protein, playing a crucial role in the development of targeted protein degradation strategies. This compound is primarily utilized in the synthesis of PROTAC SOS1 degrader-10, facilitating the degradation of specific proteins involved in oncogenic signaling pathways. Its application holds potential for advancing research in cancer therapeutics and targeted drug delivery.